PerpEquities

Takeda Pharmaceutical Company Limited (TAKEDA) financials

JPX · Healthcare · Drug Manufacturers - Specialty & Generic · 47,029 employees · CEO Julie So-Young Kim

Price
¥6,651.00 +2.78%
Market cap
¥10.6T
Enterprise value
¥14.8T
Last report
Q2 '26 filed 2026-09-30
Next report
2027-01-28 EPS est. ¥88.42
Revenue (TTM)¥4.69T+6.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)13.3%+3.3 pp vs a year agoOperating income ¥622B
Net income (TTM)¥385B+1,063.9% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)¥588B-36.9% vs a year agoCapex ¥186B
Diluted EPS (TTM)¥242.81+1,109.2% vs a year agoSum of the last 4 quarters
Net cash-¥4.12T-5.5% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
¥10.6T
EV ¥14.8T
Revenue
¥4.69T
Trailing 12 months
Revenue growth
+4%
FY2027 consensus
Profit margin
8.2%
Net income / revenue, TTM
P/E
27.2×
Forward 43.6× (FY2027)
P/S
2.3×
Price / sales, TTM
EV / EBITDA
11.2×
TTM
Free cash flow
¥588B
Trailing 12 months
Net income
¥385B
Trailing 12 months
Revenue estimate
¥4.69T
FY2027 consensus
Earnings
2027-01-28
Revenue est. ¥1.22T
Dividend
¥202.00
Per share, last 12 months

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Last report (2026-10-29): revenue beat by 2.8%, EPS beat by 165.8%Revenue ¥1.19T vs ¥1.16T expected (+2.8%); EPS ¥120.88 vs ¥45.47 (+165.8%).
  • Revenue growth accelerating: 6.7% year on yearQ2 '26 revenue ¥1.19T, against an average of 3.2% over the four quarters before.
  • Operating margin 13.3% (TTM), +3.3 pp on a year agoOperating income grew 40.9% while revenue grew 6.3%.
  • 55.5% of pre-tax profit is eaten by non-operating lossesPre-tax income ¥400B vs operating income ¥622B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
  • Capex 4.0% of revenue (a year ago 4.4%)¥186B invested in the last 4 quarters (-4.2% on a year earlier). Free cash flow ¥588B = 152.8% of net income.
  • Returned ¥317B to shareholders = 53.9% of free cash flowBuybacks ¥1.01B (a year earlier ¥102B), dividends ¥316B, stock-based pay ¥36B (TTM).
  • Diluted share count down 0.9% in a year1.56B diluted shares in Q2 '26, 1.58B a year earlier.
  • Net debt ¥4.12TCash + short-term investments ¥454B, debt incl. leases ¥4.58T; a year ago net debt ¥3.91T.

Last quarter: Q2 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q2 '26Year agoChange
Revenue¥1.19T¥1.11T+6.7%
Gross margin67.0%65.8%+1.1 pp
Operating income¥205B¥69B+197.6%
Operating margin17.3%6.2%+11.1 pp
Net income¥192B-¥11.8B+1,730.5%
Diluted EPS¥123.15-¥7.48+1,746.4%
Operating cash flow¥258B¥378B-31.8%
Capex¥44.7B¥52.8B-15.4%
Free cash flow¥213B¥325B-34.5%
R&D¥171B¥161B+6.0%
Stock-based compensation¥0¥18.7B-100.0%

Reported vs consensus

2026-10-29
ActualConsensusvs consensus
Revenue¥1.19T¥1.16T+2.8%
EPS (as estimated)¥120.88¥45.47+165.8%

From the report of 2026-10-29 for Q2 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Operating cash flow
¥775B
Capex
-¥186B
Buybacks
-¥1.01B
Dividends
-¥316B
Acquisitions
¥16.6B
Net debt issued
-¥266B
Stock-based compensation
¥36B
Free cash flow
¥588B
Returned to shareholders / FCF
53.9%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)27.2×40.3×21.3× – 64.6×
EV / EBITDA11.2×10.3×9.0× – 12.7×
EV / Sales3.1×2.7×2.6× – 2.9×
Price / FCF18.1×10.0×6.1× – 14.0×
Price / Book1.4×1.0×0.9× – 1.1×
FCF yield5.5%10.8%7.1% – 16.4%
Return on invested capital4.6%3.8%2.9% – 4.7%
Return on equity5.1%3.0%1.6% – 5.0%

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2027¥4.69T+4.1%¥152.41+27.4%43.6×9
FY2028¥4.8T+2.3%¥204.63+34.3%32.5×13
FY2029¥4.96T+3.2%¥251.32+22.8%26.5×12
FY2030¥5.3T+6.9%¥403.22+60.4%16.5×5
FY2031¥5.29T-0.2%¥341.20-15.4%19.5×6

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpenBalance sheetCash, investments, assets, debt, liabilities and equityOpenCash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates: Financial Modeling Prep.

Data as of 2026-11-01